Gilead Sciences | GILD - Cost Of Sales


Gilead Sciences reported $1.44B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 104.5M 16.68M Mar/2026
J&J USD 8.07B 103M Mar/2026
Merck USD 2.94B 380M Mar/2026
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.67B 621M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
United Therapeutics USD 133.4M 341.3M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026